Spondyloarthritis: The Changing Landscape Today, An Issue of Rheumatic Disease Clinics of North America

1st Edition, Volume 46-2 - May 8, 2020
Editors: Xenofon Baraliakos, Michael H. Weisman
Language: English
Hardback ISBN:
9 7 8 - 0 - 3 2 3 - 7 3 3 7 7 - 9
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 7 3 3 7 8 - 6

This issue of Rheumatic Disease Clinics, guest edited by Drs. Xenofon Baraliakos and Michael H. Weisman, Spondyloarthritis: The Changing Landscape Today, takes a very comprehensive… Read more

Spondyloarthritis: The Changing Landscape Today, An Issue of Rheumatic Disease Clinics of North America

Purchase options

Info / Buy

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

This issue of Rheumatic Disease Clinics, guest edited by Drs. Xenofon Baraliakos and Michael H. Weisman, Spondyloarthritis: The Changing Landscape Today, takes a very comprehensive look at all of the essential topics surrounding spondyloarthritis. This issue is one of four selected each year by Dr. Weisman, who is also our series consulting editor. This very comprehensive issue will include the following topics (among others): Molecular biology approaches to understanding SpA; Microbiome and its role in SpA; Classification criteria in axSpA; Administrative data and coding for axSpA; Approach to the patient with IBD and AxSpA; Axial PsA vs. Axial SpA with Psoriasis; Emerging imaging techniques in SpA; The future of imaging in axSpA; Treatment Recommendations vs. Treat to Target in axSpA; The future of axSpA treatmentAxSpA in the era of Precision Medicine; Quality of Life as an outcome in studies of axSpA; Gender differences in SpA; The patient’s perspective on the burden of disease in axSpA; and Juvenile SpA.

Cover image
Title page
Table of Contents
Copyright
Contributors
Forthcoming Issues
Preface
Genetics and Juvenile SpA
Pathogenesis of Axial Spondyloarthritis — Sources and Current State of Knowledge
Key points
Introduction
Epidemiology
Genetics
Imaging
Clinical trials
Tissue specimens
Blood biomarkers
In vitro studies
Animal models
A model of axial spondyloarthritis pathogenesis
Summary
Molecular Biology Approaches to Understanding Spondyloarthritis
Key points
Introduction
Genetics
Proteomics and metabolomics
Microbiome
Immune phenotyping
Integrated omics
Summary
Intestinal Microbiota, HLA-B27, and Spondyloarthritis: Dangerous Liaisons
Key points
Intestinal microbiota in spondyloarthritis: good, bad, and ugly
Innate(-like) lymphocyte responses in the gut: sensors of intestinal dysbiosis in spondyloarthritis?
HLA-B27 and the microbiota: the new kid on the block?
Concluding remarks
What Does Human Leukocyte Antigen B27 Have to Do with Spondyloarthritis?
Key points
Introduction
What is the epidemiologic distribution of human leukocyte antigen B27 around the globe?
How is human leukocyte antigen B27 tested?
Does human leukocyte antigen B27 have a physiopathologic role as well?
Does human leukocyte antigen B27 influence spondyloarthritis phenotype?
Is human leukocyte antigen B27 associated with spondyloarthritis prognosis?
How does human leukocyte antigen B27 affect referral strategies from the primary care setting?
Summary
Juvenile-Versus Adult-Onset Spondyloarthritis: Similar, but Different
Key points
Classification and nomenclature
Clinical features
Clinical outcomes
Pathogenesis
Imaging: the role of magnetic resonance imaging in evaluation of juvenile spondyloarthritis
The role of ultrasound imaging in juvenile spondyloarthritis
Summary
Referral/Diagnosis
Classification Criteria in Axial Spondyloarthritis: What Have We Learned; Where Are We Going?
Key points
Introduction
Diagnosis and classification of axial spondyloarthritis
Axial spondyloarthritis: an historical perspective
A critical view of the components of the Assessment of Spondyloarthritis International Society classification criteria for axial spondyloarthritis
The classification of axial spondyloarthritis inception cohort study
Summary
EAMs
Approach to the Patient with Axial Spondyloarthritis and Suspected Inflammatory Bowel Disease
Key points
Introduction
In which patients with axial spondyloarthritis should we suspect the presence of inflammatory bowel disease?
How should a patient diagnosed with axial spondyloarthritis and suspected inflammatory bowel disease be studied?
What results should be considered diagnostic in the biopsy?
What is the role of nonsteroidal anti-inflammatory drugs, corticosteroids and conventional synthetic disease-modifying drugs in treatment?
Which biological can be used?
Is there evidence for the use of Janus kinase inhibitors?
What is the role of smoking and body composition?
What is the risk of colorectal cancer?
Are there clinical scales for monitoring the activity of inflammatory bowel disease in patients with axial spondyloarthritis?
Summary
Imaging
Emerging Imaging Techniques in Spondyloarthritis: Dual-Energy Computed Tomography and New MRI Sequences
Key points
Introduction
Emerging imaging techniques for bone marrow edema
Emerging imaging techniques for structural lesions in spondyloarthritis
Summary
The Future of Imaging in Axial Spondyloarthritis
Key points
The current position of imaging in axial spondyloarthritis
Challenges and areas of development
Out of the comfort zone
Summary
Can Imaging Be a Proxy for Remission in Axial Spondyloarthritis?
Key points
Introduction
Clinical remission and imaging remission
Monitoring of disease activity during treatment
Correlation among imaging, clinical outcomes, and patient-reported outcomes
Imaging to predict clinical response
Imaging-driven treat-to-target strategy in spondyloarthritis
New emerging imaging modalities
Summary
Treatment and Outcomes
Axial Psoriatic Arthritis: A Distinct Clinical Entity in Search of a Definition
Key points
Introduction
Classification of psoriatic arthritis and phenotypes
Nomenclature
Genetics
Prevalence
Clinical manifestations
Imaging
Assessment
Treatment
Summary
Treat to Target in Axial Spondyloarthritis: Pros, Cons, and Future Directions
Key points
Introduction: treat to target
Defining the target: disease activity measures
Which outcomes to target
Treat-to-target trials in rheumatology
Treat to target in spondyloarthritis management guidelines
Future directions and research agenda
The Future of Axial Spondyloathritis Treatment
Key points
Introduction
New to market treatments
Treatments in trials
Summary
Axial Spondyloarthritis in the Era of Precision Medicine
Key points
Axial spondyloarthritis
Treatment in axial spondyloarthritis
Extra-articular manifestations in axial spondyloarthritis and choice of treatment
Summary
(Health-Related) Quality of Life as an Outcome in Studies of Axial Spondyloarthritis
Key points
Introduction
Frameworks relevant to develop measures for overall health or health-related quality of life
Measures of functioning and health or health-related quality of life applied in axial spondyloarthritis
Core outcomes, context, and reference shift in relation to overall health or health-related quality of life
Quality of life in axial spondyloarthritis
Summary
Patient´s perspective
The Patient’s Perspective on the Burden of Disease in Ankylosing Spondylitis
Key points
AS Patient: How to Cope with the Lifelong and Changing Disease Challenges
Key points
That’s me
How my illness developed
Voluntary work
Points to consider